Summary In the last 2 years (1989)(1990) we have treated a total of 53 patients with metastatic nonseminomatous germ cell tumours (teratoma). In ten cases surgery to remove residual abdominal masses was required on completion of chemotherapy and normalisation of tumour markers (HCG and 
The introduction of cisplatin into chemotherapy for nonseminomatous germ cell tumours (teratoma) was responsible for a dramatic improvement in the prognosis (Einhorn & Donohue, 1977) . Currently the overall cure rate for this tumour is of the order of 90% (Loehrer et al., 1988) , although for patients with the most advanced metastatic disease, the prospect of cure is somewhat lower, at approximately 40-70% (Lewis et al., 1991) . The optimal management strategy for these patients with large volume metastatic disease has not yet been fully defined.
In general, since early debulking has been shown not to improve prognosis (Javadpour et al., 1982) 
1990
Figure 3 Fall in AFP with time in patient 3. and at that stage a CT scan showed a residual 12 x 13 cm abdominal mass, as well as a residual lesion in the mediastinum and a single lung metastasis. Despite the presence of lesions above the diaphragm, a laparotomy was performed on 16.08.90. A large mass occupying the left para-colic gutter causing displacement of the kidney and surrounding the aorta was removed with complete macroscopic clearance of tumour. A left orchidectomy was also performed, and both the testis and the mass showed histological evidence of cystic areas with lining epithelium, smooth muscle and foci of cartilage formation consistent with differentiated malignant teratoma. Further chemotherapy in the form of two cycles of POMB-ACE was given post-operatively with normalisation of serum AFP. Thoracotomy was performed on 29.01.91 to remove a mass of residual differentiated teratoma from the posterior mediastinum. As this operation the single lung lesion still visible on CT scan was impalpable. The serum AFP has remained normal with no clinical evidence of relapse 7 months after completing therapy.
Discussion
As a general rule in cancer therapy, the greater the number of tumour cells present the more likely is mutation to or selection of a drug resistant phenotype during therapy. It therefore seems reasonable to expect any drug resistant cells to arise in the largest tumour masses. In all three patients detailed in this paper the response to chemotherapy was intially satisfactory as judged by falling markers, but this could not be maintained with repeated cycles of treatment, implying a degree of acquired cytotoxic drug resistance. In this situation the clinician is faced with a number of difficult decisions; can more intensive chemotherapy be safely delivered? Can different agents be substituted with a realistic expectation of cure? Should a purely palliative approach be adopted? In these patients we decided to remove surgically the largest mass, which should contain the resistant fraction of cells. The evident success of this intervention is witnessed by the fall in tumour markers that occurred in all cases even before further chemotherapy was given. It is unclear whether the cells removed were resistant because of intrinsic cellular mechanisms or more simply due to problems of drug penetration into large necrotic masses of tumour. Nevertheless, each of our patients was converted from an apparently drug resistant phase into a curable situation by the use of judiciously timed radical surgery.
An alternative explanation for this pattern of tumour marker fall in these patients is suggested in the recent publication ( Van der Gast et al., 1991) detailing two patients in whom cystic differentation occurred within the tumour with formation of cyst fluid rich in markers thereby forming a reservoir. The apparent resistance of these patients to chemotherapy was therefore fallacious. In cases 2 and 3 of this report the resected tumours did show mainly differentiated teratoma, but in both cases cells were present which stained for AFP using immunohistochemical methods and these are assumed to be the source of serum markers rather than any cyst reservoir of markers as in the cases described by Van der Gast et al. (1991) .
The traditional place of surgery in teratoma is in the initial diagnosis, and in the subsequent resection of post-chemotherapy residual masses (Einhorn et al., 1981) . Planned initial 'debulking' surgery proved to be of no value in one randomised study (Javadpour et al., 1982) , although surgery performed after three cycles of treatment in responding patients has perhaps contributed to the excellent results in one nonrandomised series of patients with advanced disease (Pizzacaro et al., 1985) . A similar treatment policy to that described in this paper was pursued by Logothetis et al. (1986) in four patients. In the light of our experience we would advocate that teratoma patients with very large masses (particularly abdominal) but small volume disease elsewhere be considered for surgical removal of the largest masses in the specific situation of attentuation of chemotherapy response as judged by serial marker estimations and CT scanning. However this must be carefully considered as inevitably not all patients will have a successful outcome (Logothetis et al., 1986) and surgical intervention might delay the introduction of alternative (perhaps more effective) chemotherapy.
Over a 2 year period in our centre, these circumstances became evident in 6% of the patients requiring chemotherapy for metastatic teratoma. Such an approach requires experience in retroperitoneal surgery on behalf of the surgeon involved and careful timing of surgery with the early involvement of the surgical team in discussions of treatment plans. In a small subgroup of patients, this combined approach may well prove to have curative potential.
